ATE427317T1 - Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane - Google Patents

Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane

Info

Publication number
ATE427317T1
ATE427317T1 AT02756777T AT02756777T ATE427317T1 AT E427317 T1 ATE427317 T1 AT E427317T1 AT 02756777 T AT02756777 T AT 02756777T AT 02756777 T AT02756777 T AT 02756777T AT E427317 T1 ATE427317 T1 AT E427317T1
Authority
AT
Austria
Prior art keywords
neuregulin
targeted
heparin binding
proteoglycan
hybrid proteins
Prior art date
Application number
AT02756777T
Other languages
German (de)
English (en)
Inventor
Jeffrey Loeb
Original Assignee
Univ Wayne State
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Wayne State filed Critical Univ Wayne State
Application granted granted Critical
Publication of ATE427317T1 publication Critical patent/ATE427317T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02756777T 2001-07-31 2002-07-31 Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane ATE427317T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US30856301P 2001-07-31 2001-07-31

Publications (1)

Publication Number Publication Date
ATE427317T1 true ATE427317T1 (de) 2009-04-15

Family

ID=23194471

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02756777T ATE427317T1 (de) 2001-07-31 2002-07-31 Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin- bindungsdomane

Country Status (8)

Country Link
US (1) US7527794B2 (enExample)
EP (1) EP1456239B1 (enExample)
JP (1) JP4314113B2 (enExample)
AT (1) ATE427317T1 (enExample)
AU (1) AU2002322762B2 (enExample)
CA (1) CA2455830C (enExample)
DE (1) DE60231833D1 (enExample)
WO (1) WO2003012045A2 (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2005271902B2 (en) * 2004-07-09 2011-12-08 Wayne State University Hybrid proteins with erbB4 extracellular domain and neuregulin heparin-binding domain for targeting
US20110034383A1 (en) * 2007-10-15 2011-02-10 Institut Pasteur Cxcl12 gamma a chemokine and uses thereof
EP2346526A2 (en) * 2008-09-22 2011-07-27 Massachusetts Institute of Technology Compositions of and methods of using ligand dimers
WO2011119836A1 (en) 2010-03-24 2011-09-29 Massachusetts Institute Of Technology Methods and compositions for cardioprotection and cardioregeneration
WO2011147981A2 (en) * 2010-05-28 2011-12-01 Mind-Nrg Sa Neuregulin isoforms, neuregulin polypeptides and uses thereof
US8961981B2 (en) 2011-06-20 2015-02-24 Saint Louis University Targeting the neuromuscular junction for treatment
US20130058871A1 (en) * 2011-07-28 2013-03-07 Howard Hughes Medical Institute Method and system for mapping synaptic connectivity using light microscopy
US9421245B2 (en) 2012-06-25 2016-08-23 The Brigham And Women's Hospital, Inc. Targeted therapeutics
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
US20170333529A1 (en) * 2015-01-20 2017-11-23 Universiteit Antwerpen Neuregulin in the treatment of fibrotic disorders
CA3012985A1 (en) 2015-01-27 2016-08-04 Kardiatonos, Inc. Biomarkers of vascular disease
WO2020142587A1 (en) 2019-01-03 2020-07-09 The Board Of Trustees Of The University Of Illinois Method and kit for treating a neurodegenerative disease
WO2021062298A1 (en) 2019-09-27 2021-04-01 Arterez, Inc. Biomarker panel targeted to diseases due to multifactorial ontology of glycocalyx disruption

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8947791A (en) * 1990-11-01 1992-05-26 Scripps Research Institute, The Glycosaminoglycan-targeted fusion proteins, their design, construction and compositions
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
WO1993022424A1 (en) * 1992-04-29 1993-11-11 Amgen Inc. RECOMBINANT STIMULATING FACTOR OF THE neu RECEPTOR
WO1994008007A1 (en) 1992-09-29 1994-04-14 President And Fellows Of Harvard College Trophic factor having ion channel-inducing activity in neuronal cells
US6037329A (en) * 1994-03-15 2000-03-14 Selective Genetics, Inc. Compositions containing nucleic acids and ligands for therapeutic treatment
JP2000510879A (ja) 1995-09-05 2000-08-22 ケンブリッジ ニューロサイエンス,インコーポレイテッド 特異的なオリゴ糖−ニューレグリン相互作用のためのアナログおよびその使用
US6344436B1 (en) * 1996-01-08 2002-02-05 Baylor College Of Medicine Lipophilic peptides for macromolecule delivery
ATE290595T1 (de) * 1996-07-12 2005-03-15 Genentech Inc Gamma-heregulin
ATE486937T1 (de) 1996-07-12 2010-11-15 Genentech Inc Chimärische heteromultimerische adhesine
KR100195886B1 (ko) 1996-11-01 1999-06-15 김상조 당뇨병 치료용 의약조성물
WO1998043649A2 (en) 1997-03-28 1998-10-08 Otsuka Pharmaceutical Co., Ltd. Age production inhibitory composition comprising a maillard reaction inhibitor and vitamin b¿6?
AU4469997A (en) * 1997-09-17 1999-04-05 Urs Eppenberger Heregulin-gamma
GB2363714B (en) 1998-04-23 2004-03-03 Vladimir Leko Herbal composition and medicament against diabetes mellitus type II manufactured thereof
CA2325919C (en) * 1999-01-29 2009-07-21 Kaneka Corporation Processes for the preparation of threo-1,2-epoxy-3-amino-4-phenylbutane derivatives

Also Published As

Publication number Publication date
EP1456239A4 (en) 2005-04-27
AU2002322762B2 (en) 2008-10-16
JP4314113B2 (ja) 2009-08-12
CA2455830A1 (en) 2003-02-13
US20050107601A1 (en) 2005-05-19
WO2003012045A3 (en) 2004-07-01
US7527794B2 (en) 2009-05-05
EP1456239A2 (en) 2004-09-15
DE60231833D1 (de) 2009-05-14
EP1456239B1 (en) 2009-04-01
CA2455830C (en) 2012-10-09
JP2005500052A (ja) 2005-01-06
WO2003012045A2 (en) 2003-02-13

Similar Documents

Publication Publication Date Title
DE60231833D1 (de) Auf heparansulfat-proteoglycane gerichtete hybridproteine mit neuregulin-heparin-bindungsdomäne
NO20001600L (no) Apolipoprotein A-1-agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
DE69738483D1 (de) Polypeptide mit phytase-aktivität und sie kodierende nukleinsäuren
NO20001599L (no) Apolipoprotein A-1 agonister og deres anvendelse for Õ behandle dyslipidemiske forstyrrelser
PL341524A1 (en) Novel receptor coupled wih g protein
BG104149A (bg) Белтъци, свързващи интерлевкин-18, тяхното получаване и приложение
NZ595498A (en) Cellulolytic enzymes, nucleic acids encoding them and methods for making and using them
BR9710357A (pt) Adesina heteromultimera quimerica recomvinante isolada sequencia de acido nucleiro isolada acido nucleico isolado vetor celula hospedeira anticorpo metodo para formar um complexo adesina-ligante heteromultimera quimerica metodo para inibir a ativa-ao metodo para ativar um receptor hetermultimerico natural composicao farmaceutica artigo manufaturado e metodo para produzir anticorpo
ATE352626T1 (de) Polypeptide mit galaktoseoxidaseaktivität und dafür kodierende nukleisäuren
DE69637874D1 (de) C-C CHEMOKIN REZEPTOR 3: CKR-3 ODER Eos-L2
EP1009814A4 (en) KDR, A HUMAN TYROSIN KINASE RECEPTOR
ATE354638T1 (de) Menschlicher gewebsinhibitor von metalloproteinase-4
ATE323770T1 (de) Polypeptide mit lysophospholipaseaktivität und nukleinesäuren die sie kodieren
ATE414775T1 (de) Polypeptide mit prolyldipeptidylaminopeptidase- aktivität und dafür kodierende nukleinsäuren
ATE450603T1 (de) Polypeptide mit verzweigungsenzym-aktivität und für diese kodierende nukleinsäuren
ATE290595T1 (de) Gamma-heregulin
WO2006017184A3 (en) HYBRID PROTEINS WITH ErbB4 EXTRACELLULAR DOMAIN AND NEUREGULIN HEPARIN-BINDING DOMAIN FOR TARGETING
EA199900522A1 (ru) Полипептиды, кодируемые геном, подобным гену липазы человека, композиции и методы
TR200200253T2 (tr) Proteinlerin üretimi
DE69929183D1 (de) G-csf-rezeptoragonist-antikörper und methode zu ihrer isolierung mittels durchmusterung
Klatt et al. The matrilin-3 VWA1 domain modulates interleukin-6 release from primary human chondrocytes
DE60031414D1 (de) Einkettige polypeptide enthaltend n-terminale troponin i fragmente und troponin c
BR0007816A (pt) Fator de estimulação óssea
Qiang et al. Discovery of a Novel Cysteine Framework XXIV Conotoxin from Conus striatus, S24a, with Potential Analgesic Activity
WO2000055192A3 (de) Hämocyanin und dafür kodierende nukleinsäuresequenz

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties